Pharmaceuticals
with passion

Corporate

M&A for growth, 20 years of M&A in Italy, the best deals of 2023

Alfasigma S.p.A has been selected as a finalist in the 20th edition of the M&A Awards: 20 Years of M&A in Italy, The Best Deals Of 2023, the initiative promoted by KPMG and Fineurop Soditic Spa, with the collaboration of Borsa Italiana and Class Editori, under the patronage of Bocconi University and AIFI, which rewards the best M&A transactions. The awards celebrate the importance of M&A as a strategic lever for business growth and competitiveness. Alfasigma has been shortlisted in the “Italian Acquisitions Abroad” category by a highly prestigious jury of industry experts, for the acquisition of Intercept Pharmaceuticals, Inc. 

Read more
Corporate

Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million

Bologna, 31 January 2024, 22:01 CET – Alfasigma S.p.A. is pleased to announce the successful completion of the transaction to acquire the Jyseleca® (filgotinib) business from Galapagos NV (Euronext & NASDAQ: GLPG) for up to €170 million. This marks a significant milestone for the company’s international growth strategy and follows both the signing of the agreement announced on 2 January 2024 and of the Letter of Intent announced on 30 October 2023.

Read more

Therapeutic areas

Gastroenterology

Gastrointestinal therapeutics are our specialty. Everyday we strive to give a concrete answer to functional gastro-intestinal disorders, IBD (Inflammatory Bowel Disease), gastro-oesophageal reflux disorder, hepatic encephalopathy and chronic liver disease (cirrhosis), Ulcerative Colitis, PBC (Primary Biliary Cholangitis)

Vascular

Vascular investigation is a company corporate mission. Venous diseases, lower extremity artery disease, diabetic microangiopathies are the main pathologies in which we offer solutions

Rheumatology

We provide treatments to relieve symptoms and signs in patients affected by rheumatoid arthritis

Metabolic

In the metabolic area, our R&D has developed Carnitine, an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscles

Nutraceuticals & Medical foods

With our supplements, we are responding to the demand for a vast range of elements aimed at neural tissue well-being, recovery of muscle tone and combating physical and mental fatigue

CSR

Alfasigma's business strategy is closely linked to the principles of sustainability. We support scientific popularization and play a proactive role in the areas of culture, art, and civil society. We recognize that a pharmaceutical company is also a cultural entity. The dignity of a person is not only about being healthy, but encompasses all aspects of life and the environment in which they live, reflecting an idea of the overall well-being of society.

×

You’re entering Alfasigma global website

I agree